Alterity Therapeutics Ltd (fra:PBN) Share Price

Company Profile

Business description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
Contact
500 Collins Street
Level 15
MelbourneVIC3000
AUS
T: +61 393494906
E: [email protected]
https://www.alteritytherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
11

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,921.00	15.20	0.17%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,193.94	100.57	0.44%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,503.82	189.34	-0.30%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,805.60	10.40	0.12%
SSE Composite Index	3,683.92	6.56	-0.18%